Site is Being Upgraded

Mechanistic insights into how Antiarrhythmic/Local anesthetic agent Pilsicainide may deteriorate memory, learning, and cognition: Pilsicainide (trade name: Sunrythm) decreases Tissue inhibitor of metalloproteinases 2 (TIMP2) and BDNF levels, attenuates cognition, and aggravates age-associated decline in memory and learning, via up-regulation of its target genes, 9/October/2018, 11.56 am

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Mifepristone, an abortion-promoting drug, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 11.24 am
October 9, 2018
The PD1-PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Temozolomide, Mevastatin, Cyclabezaprine, Hydralizine, SNX5422, Salinomycin (TMCHSS) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 12.16 pm
October 9, 2018
Show all

Introduction: What they say

A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, California 94305, USA Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California 94305, USA; Center for Tissue Regeneration, Repair and Restoration, V.A. Palo Alto Healthcare System, Palo Alto, California 94304, USA shows that “Human umbilical cord plasma proteins revitalize hippocampal function in aged mice.” This research paper was published, in the 19 April 2017 issue of the journal “Nature” [One of the best research journals in General sciences with an I.F of 43+], by Prof.Tony Wyss-Coray, Joseph M. Castellano and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic insights into how Antiarrhythmic/Local anesthetic agent Pilsicainide may deteriorate memory, learning, and cognition: Pilsicainide (trade name: Sunrythmdecreases Tissue inhibitor of metalloproteinases 2 (TIMP2) and BDNF levels, attenuates cognition, and aggravates age-associated decline in memory and learning, via up-regulation of its target genes


What is known?

Prof.Tony Wyss-Coray’s research team has recently shown that:  (1) human cord plasma treatment promotes cognitive and learning function in aged mice; (2) blood-borne component Tissue inhibitor of metalloproteinases 2 (TIMP2) is enriched in human cord plasma, young mouse plasma, and young mouse hippocampi; (3) TIMP2 increases hippocampal-dependent cognition; and (4) treating brain slices with TIMP2 antibody inhibits long-term potentiation and prevents hippocampal function, suggesting that increasing the expression of TIMP2 in aged individuals may enhance learning and memory.


 

From Research findings to Therapeutic opportunity:

This study provides mechanistic insights into how repeated and the prolonged use of Antiarrhythmic/Local anesthetic agent Pilsicainide may attenuate cognition,  memory, and learning. Pilsicainide, by increasing the expression of its target genes, may decrease the levels of TIMP2 and BDNF. Thereby, it may: (1) attenuate cognition and learning; (2) diminish spatial memory; and (3)  deteriorate hippocampal function (fig.1).

 

Figure1. Mechanistic insights into how the antiarrhythmic agent Pilsicainide may diminish learning, memory, and cognition. Lidocaine, by decreasing the expression of TIMP2, it decreases learning and memory in aged individuals.

Figure 2. John B. (Iain) Glen, who won the 2018 Lasker Clinical Medical Research Award (America’s Nobel), discovered the anesthetic agent Propofol. Antiarrhythmic/Local anesthetic agent Pilsicainide, by increasing the expression of its target genes, it may attenuate TIMB2 and BDNF expression. And thereby, it may attenuate learning, memory, and cognition


 

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Pilsicainide decreases the levels of TIMP2 and BDNF and attenuates memory and learning

Amount: $500#

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Mechanistic insights into how Antiarrhythmic/Local anesthetic agent Pilsicainide may deteriorate memory, learning, and cognition: Pilsicainide (trade name: Sunrythmdecreases Tissue inhibitor of metalloproteinases 2 (TIMP2) and BDNF levels, attenuates cognition, and aggravates age-associated decline in memory and learning, via up-regulation of its target genes, 9/October/2018, 11.56 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.